1 Ocak 2021 Dergi makalesi Açık Erişim

Tekintas, Yamac; Demir-Dora, Devrim; Erac, Bayri; Erac, Yasemin; Yilmaz, Ozlem; Aydemir, Sabire Sohret; Kocagoz, Zuhtu Tanil; Hosgor-Limoncu, Mine

DataCite XML

<?xml version='1.0' encoding='utf-8'?>
<resource xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://datacite.org/schema/kernel-4" xsi:schemaLocation="http://datacite.org/schema/kernel-4 http://schema.datacite.org/meta/kernel-4.1/metadata.xsd">
  <identifier identifierType="URL">https://aperta.ulakbim.gov.tr/record/237788</identifier>
  <creators>
    <creator>
      <creatorName>Tekintas, Yamac</creatorName>
      <givenName>Yamac</givenName>
      <familyName>Tekintas</familyName>
      <affiliation>Izmir Katip Celebi Univ, Fac Pharm, Dept Pharmaceut Microbiol, Izmir, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Demir-Dora, Devrim</creatorName>
      <givenName>Devrim</givenName>
      <familyName>Demir-Dora</familyName>
    </creator>
    <creator>
      <creatorName>Erac, Bayri</creatorName>
      <givenName>Bayri</givenName>
      <familyName>Erac</familyName>
      <affiliation>Ege Univ, Fac Pharm, Dept Pharmaceut Microbiol, Izmir, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Erac, Yasemin</creatorName>
      <givenName>Yasemin</givenName>
      <familyName>Erac</familyName>
      <affiliation>Ege Univ, Fac Pharm, Dept Pharmacol, Izmir, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Yilmaz, Ozlem</creatorName>
      <givenName>Ozlem</givenName>
      <familyName>Yilmaz</familyName>
    </creator>
    <creator>
      <creatorName>Aydemir, Sabire Sohret</creatorName>
      <givenName>Sabire Sohret</givenName>
      <familyName>Aydemir</familyName>
      <affiliation>Ege Univ, Fac Med, Dept Med Microbiol, Izmir, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Kocagoz, Zuhtu Tanil</creatorName>
      <givenName>Zuhtu Tanil</givenName>
      <familyName>Kocagoz</familyName>
      <affiliation>Acibadem Mehmet Ali Aydinlar Univ, Sch Med, Dept Med Microbiol, Istanbul, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Hosgor-Limoncu, Mine</creatorName>
      <givenName>Mine</givenName>
      <familyName>Hosgor-Limoncu</familyName>
      <affiliation>Ege Univ, Fac Pharm, Dept Pharmaceut Microbiol, Izmir, Turkey</affiliation>
    </creator>
  </creators>
  <titles>
    <title>Silencing Acpp Gene Via Antisense Oligonucleotide-Niosome Complex In Clinical Pseudomonas Aeruginosa Isolates</title>
  </titles>
  <publisher>Aperta</publisher>
  <publicationYear>2021</publicationYear>
  <dates>
    <date dateType="Issued">2021-01-01</date>
  </dates>
  <resourceType resourceTypeGeneral="Text">Journal article</resourceType>
  <alternateIdentifiers>
    <alternateIdentifier alternateIdentifierType="url">https://aperta.ulakbim.gov.tr/record/237788</alternateIdentifier>
  </alternateIdentifiers>
  <relatedIdentifiers>
    <relatedIdentifier relatedIdentifierType="DOI" relationType="IsIdenticalTo">10.1016/j.resmic.2021.103834</relatedIdentifier>
  </relatedIdentifiers>
  <rightsList>
    <rights rightsURI="http://www.opendefinition.org/licenses/cc-by">Creative Commons Attribution</rights>
    <rights rightsURI="info:eu-repo/semantics/openAccess">Open Access</rights>
  </rightsList>
  <descriptions>
    <description descriptionType="Abstract">Pseudomonas aeruginosa, an opportunistic Gram-negative pathogen, is one of the major causes of nosocomial infections. In addition to its physiological adaptation capacity, it can develop resistance to disinfectants and antibiotics through various mechanisms. Recently, new eradication methods are gaining attention. Therefore, in this study, an LNA-2'-O-methyl hybrid antisense oligonucleotide targeting the acyl carrier protein P (acpP) gene was introduced into P. aeruginosa isolates. The design was determined through sequence analysis and prediction of the secondary structure of mRNA by software. Niosomes were used for enhancing cellular uptake. The control of the binding and transfection ability of the sequence was determined fluorometrically by labeling with 6-Fam. The effects were determined with broth microdilution method and qPCR studies. Eight different formulations were prepared. Among these, one formulation has shown to have ASO complexation ability whose composition was 312 mu l Span 80 + 69.5 mg Cholesterol+ 36.4 mg CTAB+1 ml Chloroform and 5 ml dH(2)O. Thus this formulation was determined as the delivery system for the next stages. Significant gene inhibition was detected at the six isolates. Results of this study suggested that niosomes can be used as a delivery system for cellular uptake of ASO and could eliminate bacterial growth. (C) 2021 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved.</description>
  </descriptions>
</resource>